Rochelle Bardis, APRN
Nurse Practitioner · Ponte Vedra, FLNPI 1932685856
Payments from drug & device makers
Across 221 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$792
- Pfizer$454
- Merck$438
- Amgen$333
- Johnson & Johnson$256
- Boehringer Ingelheim$231
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,324100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $792 |
| Pfizer | 24 | $454 |
| Merck | 24 | $438 |
| Amgen | 21 | $333 |
| Johnson & Johnson | 14 | $256 |
| Boehringer Ingelheim | 11 | $231 |
| Esperion Therapeutics, Inc. | 13 | $218 |
| Boston Scientific | 6 | $163 |
| Philips North America LLC | 5 | $142 |
| Sanofi-aventis U.S. LLC | 5 | $114 |
| Alnylam Pharmaceuticals Inc. | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $91 |
| Bayer | 4 | $90 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $83 |
| Actelion Pharmaceuticals US, Inc. | 3 | $79 |
| Novo Nordisk | 3 | $70 |
| AstraZeneca | 3 | $55 |
| Abbott | 2 | $45 |
| Abiomed | 2 | $44 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Endotronix, Inc. | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Itamar Medical Inc | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $15 |
How this compares
$4,324 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $184,667 |
| EntrestoSacubitril/Valsartan | 112 | $121,942 |
| XareltoRivaroxaban | 55 | $57,912 |
| FarxigaDapagliflozin Propanediol | 39 | $36,233 |
| JardianceEmpagliflozin | 35 | $36,090 |
| BrilintaTicagrelor | 37 | $29,763 |
| Repatha SureclickEvolocumab | 21 | $18,295 |
| VascepaIcosapent Ethyl | 20 | $11,945 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $9,748 |
| Valsartan | 141 | $4,144 |
| Ranolazine ErRanolazine | 31 | $2,491 |
| Metoprolol Succinate | 165 | $2,293 |
| Nifedipine ErNifedipine | 61 | $2,132 |
| Candesartan Cilexetil | 46 | $1,554 |
| Carvedilol | 163 | $1,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $454 | $184,667177 claims |
| NovartisEntresto | $792 | $121,942112 claims |
| AstraZenecaFarxiga, Brilinta | $55 | $65,99676 claims |
| Johnson & JohnsonXarelto | $256 | $57,91255 claims |
| Boehringer IngelheimJardiance | $231 | $36,09035 claims |
| Esperion Therapeutics, Inc.Nexlizet | $218 | $9,74815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Ponte Vedra
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.